

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/699,281 10/30/2003		Paul K. Wolber	10030355-1	3574	
22878	7590 03/07/2007 CHNOLOGIES INC	EXAMINER			
AGILENT TECHNOLOGIES INC. INTELLECTUAL PROPERTY ADMINISTRATION, LEGAL DEP			CROW, ROBERT THOMAS		
MS BLDG. E P.O. BOX 7599 LOVELAND, CO 80537			ART UNIT	PAPER NUMBER	
EO VEERINE,	, 00 00337		1634		
				DEL WEDV MODE	
			MAIL DATE	DELIVERY MODE	
			03/07/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

-	IL.
^	w
' 1	*
,	v

Advisory Action

Application No.	Applicant(s)		
10/699,281	WOLBER ET AL.		
Examiner	Art Unit		
Robert T. Crow	1634		

Before the Filing of an Appeal Brief		Examiner	Art Unit				
19.1		Robert T. Crow	1634				
	The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress			
ГΗЕ	REPLY FILED <u>06 February 2007</u> FAILS TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.				
	The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:						
	The period for reply expiresmonths from the mailing date of the final rejection. The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
	The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th				
<u>AME</u>	NDMENTS						
3	 (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE belo (c) They are not deemed to place the application in be appeal; and/or 	onsideration and/or search (see NO ow); tter form for appeal by materially re	TE below); educing or simplifying				
	(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).			(DTOL 224)			
_	The amendments are not in compliance with 37 CFR 1.1 Applicant's reply has overcome the following rejection(s)		Impliant Amendment	(PTOL-324).			
3. [Newly proposed or amended claim(s) would be a non-allowable claim(s).	llowable if submitted in a separate,	·	_			
7. ⊠	For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: None. Claim(s) objected to: None. Claim(s) rejected: 1-13 and 21-25. Claim(s) withdrawn from consideration: 14-20 and 26-28.	vided below or appended.	ill be entered and an o	explanation of			
AFF	DAVIT OR OTHER EVIDENCE	•					
3. [The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).						
	The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe ry and was not earlier presented. S	al and/or appellant fa See 37 CFR 41.33(d)(ils to provide a 1).			
	☐ The affidavit or other evidence is entered. An explanation to the control of t	on of the status of the claims after e	entry is below or attac	hed.			
	The request for reconsideration has been considered by See Continuation Sheet.		n condition for allowa	nce because:			
	☐ Note the attached Information Disclosure Statement(s).☐ Other:		Much	<u>, </u>			
		ofwall SUPERVI	M R. SHUKLA, PH.I SORY PATENT EX	D. AMINER			

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Continuation of 11. does NOT place the application in condition for allowance because: Regarding the rejection of claims 1-13 under 35 USC 103(a), Applicant argues on pages 8-10 of the Remarks that the combined teachings of McGall in view of Weng et al do not teach detection of complexes between the depurination probes and a target nucleic acid.

However, as indicated on pages 4-6 of the previous Office Action, McGall teaches detection of depurination probes by cleavage of said depurination proves after exposure to a test condition (Figure 8 and column 9, lines 39-49). The detection of McGall comprises detecting remaining label from the uncleaved oligonucleotides that are still complexed on the array (column 9, lines 50-67). Complexes of the depurinated probes are cleaved as well; thus, all of the depurination probes on the array are detected by the absence of label. The group of cleaved depurination probes includes depurination probes that were present in complexes; thus, the cleavage step detects all depurination probes, including those that were in complexes.

While McGall teaches the test conditions include operating conditions (column 11, lines 20-41) and that operating conditions include hybridization of nucleic acids to the array (column 13, lines 33-57), the specific embodiment of hybridization of a nucleic acid, which is a target, to the array followed by cleavage is not explicitly taught by McGall.

However, Weng et al teach hybridizing nucleic acids in the form of mRNA, which are targets, to a microarray as a test condition (column 4, lines 58-67 and column 8, lines 60-67). Weng et al thus clearly teach the step of hybridizing a target nucleic acid (i.e., the mRNA) to an array as a test condition. The array test condition of Weng et al is the modification applied to the test condition of McGall, which results n the added benefit of controlling the quality of the array production process as taught by Weng et al (column 5, lines 29-32).

The modification of the teachings of McGall with the target hybridization test condition of Weng et al therefore results in a method comprising all of the steps of the instant claims. The "resultant binding complexes" of the previous version of the claims were previously interpreted as binding complexes between the depurination probe and the target nucleic acid because of the limitation "resultant" that was present in the previous version of the claims. The same rejections would therefore be applied. The determination of the depurination event taught by McGall would occur as a result of detecting the binding complexes between the target nucleic acids and the depurination probes. McGall achieves this by comparing a first cleaved area of the array with a second identical uncleaved area of the array (column 9, lines 61-67). The cleavage step results in the detection of all of depurination probes, including depurination probes that were present in complexes. Thus, the cleavage step detects all depurination probes, including those that were in complexes. The complexes are detected by the absence of a signal in the treated area.

As stated in the previous Office Action, the ordinary artisan would have been motivated to make the modification because the modification would have resulted in a method of detecting depurination reaction products that has the added advantage of controlling the quality of the array production process as taught by Weng et al (column 5, lines 29-32).

Regarding the rejection of claims 21-25 under 35 USC 102(b) as anticipated by McGall, Applicant argues on pages 6-8 of the Remarks that McGall does not teach detection of the binding complexes between the depurination probe and the target nucleic acid. However, the amended claims would be rejected under 35 USC 103(a) for the reasons set forth in the rejection of claims 1-13 under 35 USC 103(a) as indicated in the previous Office Action and as outlined above.

RAM R. SHUKLA, PH.D.
SUPERVISORY PATENT EXAMINER

SUPERVISORY PATENT EXAMINER